

CORRESPONDENCE

**Gender Identity Disorders in Childhood and Adolescence: Currently Debated Concepts and Treatment Strategies**

by Dr. med. Alexander Korte, Dr. med. David Goecker, Prof. Dr. med. Heiko Krude, Prof. Dr. med. Dipl.-Psych. Ulrike Lehmkuhl, Prof. Dr. med. Annette Grüters-Kieslich, Prof. Dr. med. Dr. phil. Klaus Michael Beier in volume 48/2008

**Irreversible Physical Changes**

The authors advocate the use of puberty blocking LHRH analogues in adolescents with a gender identity disorder "after the individual's psychosexual development is complete", at the earliest. This is not consistent with the published treatment recommendations of others and does not follow the recommendations of the North American Endocrine Society—to be released for publication shortly—which recommends suppressing puberty once genital development has reached Tanner stage 2-3, and which deems that treatment with hormones of the opposite sex is indicated from age 16.

As soon as a diagnosis of transsexualism has been made by child and adolescent psychiatrists, we think that it is not acceptable to withhold hormone therapy from the affected patients and thereby practically force them to experience the irreversible physical changes that puberty visits on their bodies.

DOI: 10.3238/arztebl.2009.0318a

**REFERENCES**

1. Hembree WC, Cohen-Kettenis P, Delamarre HA, Gooren LJ, Meyer WJ, Spack NP, Tangpricha V, Montori VM: Endocrine treatment of transsexual persons: an endocrine society clinical practice guideline developed by a task force. In press.
2. Korte A, Goecker D, Krude H et al.: Gender identity disorders in childhood and adolescence—currently debated concepts and treatment strategies. Dtsch Arztebl Int 2008; 105(48): 834–41.

**Dipl.-Med. Jens Jacobsen**  
**Dr. med. Achim Wüsthof**  
 Endokrinologikum  
 Zentrum für Hormon- und Stoffwechselerkrankungen  
 Reproduktionsmedizin und Pränatale Medizin  
 Lornsenstr. 4–6  
 22767 Hamburg, Germany  
 achim.wuesthof@endokrinologikum.com

**In Reply:**

In our opinion, a diagnosis of transsexualism (in the sense of a lasting, profound transposition of gender identity) should be considered in adolescents

- only as the result of interdisciplinary collaboration between psychiatrists and specialists in sexual medicine (and should thus not be the responsibility of child and adolescent psychiatrists only), and is
- possible only after the patient's preference with regard to sexual orientation has been analyzed (while his/her native hormone status remains unchanged—i.e. before he/she receives hormone therapy).

By its nature, the latter is not possible before the psychosexual development has been completed. If these conditions for a diagnosis are met then—and only then—we think that hormonal interventions may be justified in the individual case; however, the indication should not be tied in with the patient's age.

The recommendations of the US Endocrine Society, which are referenced in the letter, entail the risk of forgetting this important issue: that the main assessment criterion should not be the reduced view on the patient's Tanner stage and chronological age, but the degree of psychosexual maturity, and that large differences exist between individuals with regard to the timing of the relevant, completed psychosexual maturation process.

A phrase such as "practically force (the patients) to experience the irreversible physical changes" seems further proof that this debate is sometimes not being conducted in a matter of fact fashion, but in a highly emotional way. However, we thank the correspondent for the comment that interdisciplinary exchange is required and research urgently needed. With regard to the unsatisfactory data situation, all those active in treating patients in this difficult field cannot but acknowledge that there are currently no scientifically proven criteria that seem to justify early hormonal intervention.

DOI: 10.3238/arztebl.2009.0318b

**REFERENCES**

1. Korte A, Goecker D, Krude H et al.: Gender identity disorders in childhood and adolescence—currently debated concepts and treatment strategies. Dtsch Arztebl Int 2008; 105(48): 834–41.

**Dr. med. Alexander Korte**  
 Klinik für Psychiatrie,  
 Psychosomatik und Psychotherapie  
 des Kindes- und Jugendalters  
 Charité - Universitätsmedizin Berlin  
 Augustenburger Platz 1, 13353 Berlin, Germany  
 alexander.korte@charite.de

**Conflict of interest statement**

The authors of the letter and of the reply declare that no conflict of interest exists according to the guidelines of the International Committee of Medical Journal Editors.